EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses

Weihong Zeng iD, Guanying Zhang, Huan Ma iD, Lijun Xiong, Mingshi Xu, Shanshan Wang, Xiaoxue Huang, Shi Chen, Xiangyang Chi iD, Sandra Chiu iD, Tengchuan Jin iD

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00608-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Weihong Zeng und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical and Environmental Engineering, Hefei Institute of Technology, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Epitopes, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hefei Municipal Key Technology Research and Development Program, Hefei Institute of Technology Talent Scientific Research Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 (SARS2) and SARS-CoV (SARS1) viruses pose significant threats due to their high mutation rates and potential for cross-species transmission, which has rendered many antibodies ineffective. To counter potential future emergences of novel SARS-like viruses, it is imperative to develop nanobodies with broad-spectrum neutralizing capacity. Here, we employed an alternating immunization strategy in alpacas using SARS1 and SARS2 RBDs to generate cross-reactive nanobodies. Four crossing-binding nanobodies (aSR29, aSR196, aSR347, and aSR348) were identified, exhibiting high affinities for SARS1/SARS2 RBDs and Omicron subvariants. Structural analysis revealed that aSR29 targets a cryptic, highly conserved epitope at the inner base of the RBD, a region shielded from conventional antibodies by steric hindrance, efficiently neutralizing SARS1, SARS2, and multiple Variants of Concern (VOCs), including XBB.1.5 and BQ.1.1. Building on this unique binding mode, we engineered a bispecific fusion protein, aSR29-ACE2-Fc. This construct synergistically combines high-affinity RBD binding with the steric blockade of viral attachment, resulting in a 33-fold increase in neutralization potency against SARS2 and enhanced resilience against immune escape. Our findings validate an efficient strategy for eliciting broad-spectrum nanobodies and demonstrate the therapeutic potential of VHH-ACE2 fusion proteins against current and future SARS-like viruses. IMPORTANCE The continued evolution of SARS-CoV-2 has rendered most existing antibodies ineffective, highlighting the urgent need for broad-spectrum countermeasures against current and future SARS-like viruses. Here, we developed an alternating immunization strategy to generate nanobodies that target a hidden, highly conserved region on the viral spike protein. One such nanobody, aSR29, potently neutralizes diverse variants, including XBB.1.5 and BQ.1.1. By fusing aSR29 with the viral receptor ACE2, we created a bispecific molecule that blocks viral entry through two independent mechanisms, achieving a 33-fold increase in neutralization potency. This work provides a practical and scalable strategy for pandemic preparedness, demonstrating that engineered nanobody–ACE2 fusions can serve as effective broad-spectrum therapeutics against emerging SARS-like viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesEpitopesAntibodies, NeutralizingAntibodies, ViralAngiotensin-Converting Enzyme 2SARS-CoV-2Spike Glycoprotein, CoronavirusSevere acute respiratory syndrome-related coronavirusAnimalsCamelids, New WorldHumansNeutralization TestsCross Reactions

Stichwörter der Autor:innen

ACE2 fusion proteinSARS-like coronavirusesalternating immunizationconserved RBD epitopenanobodies

Substanzen

Single-Domain AntibodiesEpitopesAntibodies, NeutralizingAntibodies, ViralAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • School of Biomedical and Environmental Engineering, Hefei Institute of Technology, Hefei, Anhui, China.
  • Laboratory of Structural Immunology, State Key Laboratory of Immune Response and Immunotherapy, Institute of Advanced Technology, University of Science and Technology of China, Hefei, Anhui, China.
  • National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Institute of Clinical Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, Anhui, China.

ORCID-Profile: Weihong Zeng, Huan Ma, Xiangyang Chi, Sandra Chiu, Tengchuan Jin

Förderung

  • National Natural Science Foundation of China
  • Hefei Municipal Key Technology Research and Development Program
  • Hefei Institute of Technology Talent Scientific Research Fund Project
  • Strategic Priority Research Program of the Chinese Academy of Sciences
  • USTC Research Funds of the Double First-Class Initiative
  • Anhui Provincial Higher Education Quality Engineering Project

Zitieren

APA

Zeng, W., Zhang, G., Ma, H., Xiong, L., Xu, M., Wang, S., Huang, X., Chen, S., Chi, X., Chiu, S., & Jin, T. (2026). ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00608-26

Vancouver

Zeng W, Zhang G, Ma H, Xiong L, Xu M, Wang S, et al. ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00608-26

BibTeX
@article{Zeng2026,
  author = {Zeng, Weihong and Zhang, Guanying and Ma, Huan and Xiong, Lijun and Xu, Mingshi and Wang, Shanshan and Huang, Xiaoxue and Chen, Shi and Chi, Xiangyang and Chiu, Sandra and Jin, Tengchuan},
  title = {ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00608-26}
}
Kostenlos starten →